Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 27;119(4):480–486. doi: 10.1038/s41416-018-0187-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Cancer Research UK 2018

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

PMC Copyright notice

Fig. 2 — Kaplan–Meier survival analysis considering ProMisE subgroups and L1CAM expression. OS and DSS of ProMisE subgroups before (a, b) and after (c and d) stratifying for L1CAM status within the p53 wt/NSMP subgroup. a Five-year OS rates of 87.3% for POLE tumours, 85.2% for p53 wt/NSMP tumours, 75.0% for MMR-D tumours, and 39.6% for p53 abn tumours (p < 0.001). b Five-year DSS rates of 97.6% for POLE tumours, 93.6% for p53 wt/NSMP tumours, 84.7% for MMR-D tumours, and 54.8% for p53 abn tumours (p < 0.001) c Five-year OS rates of 87.3% for POLE tumours, 88.2% for p53 wt/NSMP, L1CAM negative tumours, 75.0% for MMR-D tumours, 51.5% for p53 wt/NSMP, L1CAM-positive tumours and 39.6% for p53 abn tumours (p < 0.001) d Five-year DSS rates of 97.6% for POLE tumours, 95.5% for p53 wt/NSMP, L1CAM negative tumours, 84.7% for MMR-D tumours, 65.5% for p53 wt/NSMP, L1CAM-positive tumours and 54.8% for p53 abn tumours for disease-specific 5-year survival (p < 0.001)